^Sanchez-Lorenzo L, Sancho L, Iscar T, Grisham R, Chiva L. Management challenges in low-grade serous ovarian cancer with a BRCA mutation. Int J Gynecol Cancer. 2024 Apr 1;34(4):631-636. doi: 10.1136/ijgc-2023-005240. PMID: 38561200....
TP53mutationTP53 protein accumulationovarian carcinomaprognosisWe conducted the present study to evaluate the frequency and prognostic importance on long-term survival of TP53 mutations and TP53 protein accumulation in a cohort of 178 patients with early-stage ovarian carcinomas. TP53 mutations scored as ...
In the formation of the disease, fallopian tube epithelial (FTE) cells—ovarian cancer progenitor cells—accrue a TP53 mutation and metastasize to the ovary or omentum. To survive in suspension in the peritoneal cavity, FTE cells must evade anoikis, a form of apoptosis that occurs when anchorage...
A section from a breast carcinoma with TP53 mutation was used as a positive immunohistochemical control. Statistics Differences in proportions were evaluated by the χ2 test. Disease-free survival was defined as the time interval between diagnosis and relapse of ovarian cancer. The method of Kaplan...
[7] Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004; 64:7678–7681. [8] Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. ...
Section > Chapter Zhang, Y.; Cao, L.; Nguyen, D.; Lu, H. Translational Cancer Research 5(6): 650-663 2016 ISSN/ISBN:2218-676X 30613473 10.21037/tcr.2016.08.40 066063382 Article emailed within 0-6 h Buy Now for$19.90 Payments are secure & encrypted ...
In ovarian cancer, the high frequency of TP53 mutation (490%) and the lack of other frequently mutated genes leads to a distribution of protein variants that includes only p53 mutants (Supplementary Figures 1A–G). This analysis clearly shows that mutant p53 are among the most frequent protein...
(1994). p53 expression, mutation, and allelic deletion in ovarian cancer. J. Pathol., 174, 159-168. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D AND LEVINE AJ. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69,...
In addition to the 9 null type mutations, a splice junction mutation was encountered. In conclusion, we have observed a high prevalence (13%) of ovarian tumours with null type mutations in exons 5-8 that did not result in immunostaining. Our data suggest that, especially in ovarian...
Mutation of TP53 is a frequent event in many tumor types including epithelial ovarian cancer. Molecular genetic alteration of TP53, such as overexpression or mutation, is common in advanced epithelial ovarian carcinoma. Immunohistochemical studies demonstrate that staining for mutated p53 is essentially ...